UTv Videos

"One of the things I think that's really interesting is we're seeing the development of a lot of AI predictive models of who might progress to urosepsis and who might be at higher risk for progression of their infection to have greater health consequences," says A. Lenore Ackerman, MD, PhD.

"Of those that met the primary end point, they remained free of progression at a median of 31 months and counting," says Nicholas G. Nickols, MD, PhD.

"The evolution is continuing, now with a decade of human use of Aquablation, we can now take this to a same-day procedure––discharge the same calendar day," says Kevin C. Zorn, MD, FRCSC, FACS.

"[One] of the things that makes the technology really interesting, in my mind, for CVAC, is that it's not just a suction device," says Thomas Chi, MD, MBA.

“What probably should be happening is that we should be reserving these antibiotics only for those situations in which someone has a multi-drug-resistant infection for which there are options that are not available otherwise,” says A. Lenore Ackerman, MD, PhD.

"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a multi-institutional, prospective manner," says Shyam Natarjan, PhD.

"My specific career path is really not at all like my mentors, and I think that's fine, actually. It's great, because I'm doing what I want to do and not feeling constrained to go down any particular pathway," says Stacy Loeb, MD, MSc, PhD (Hon).

"From a revenue, profit and loss perspective, actually, in many instances, they anticipate that physicians may actually make more money using the second-generation CVAC device compared to traditional ureteroscopy, depending on your payer mix and your practice," says Thomas Chi, MD, MBA.

The TiNivo-2 trial demonstrated that rechallenging ICI therapy does not improve outcomes in patients with renal cell carcinoma.

“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says Fred Saad, MD, FRCS.

“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD.

“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP.

"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.

“[We’re] trying to anticipate with a smartwatch some of the catastrophic blood pressure changes and things that happen in these patients,” says Matthew J. Mellon, MD, FACS.

Thomas Chi, MD, MBA, discusses advantages to the CVAC System.

"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS.

“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn't know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.

“I think that there will probably be much more accessible tools within the next 5 years, and almost certainly within the next 10 years,” says Yair Lotan, MD.

"It's really upon us, as the medical community, to be better about not just antibiotic stewardship, but also diagnostic stewardship," says A. Lenore Ackerman, MD, PhD.

"That's probably the biggest thing that I would say to somebody who's interested in urology is, do you think you can get on another patient's level?" says Emily Sopko, CNP.

"What we demonstrated was that at 30-day and 90-day interval outcomes, the patients actually had equivalent safety profiles compared to traditional ureteroscopy with basketing," says Thomas Chi, MD, MBA.

"We see use of AI-generated cancer maps in the decision-making process of understanding who is the right patient for what therapy, as well as planning out the specific therapy," says Shyam Natarajan, PhD.

"I like working alongside the residents, because they've taught me pretty much everything that I know about urology," says Emily Sopko, CNP.

“So, I think we have to be conscious that when we're developing these tools that we're inclusive,” says Yair Lotan, MD.

"We found that the performance of Unfold AI was actually an AUC of .89," says Shyam Natarajan, PhD.

“The technology is there, the experience is there now, and it's bringing it all together to lead to better outcomes [and a] shorter hospital stay,” says Kevin C. Zorn, MD, FRCSC, FACS.

"Often, we can do flexible cystoscopies for difficult Foley placements, or if we need to remove an indwelling stent at the bedside, I can assist with those things," says Emily Sopko, CNP.

“It's still relatively early, but this study in close to 1000 patients validated this algorithm, and it's now being studied prospectively as well,” says Yair Lotan, MD.

"From the perspective of lifestyle medicine, what is most important is what the patient is most motivated to work on in the here and now," says Stacy Loeb, MD, MSc, PhD (Hon).

“You're going to be able to use these catheters over time, for long periods," says Ana Lidia Flores-Mireles, PhD.